Oyvind Dahle works with organizations to provide patent protection of technologies, such as chemical compounds and polymers, pharmaceutical compositions and delivery systems; immunotherapeutics using engineered antigen binding proteins, such as multispecific immunoglobulin-based molecules and chimeric antigen receptor T cell receptors; stem cell therapy; genetic modification technologies, such as Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR); artificial intelligence-based drug discovery and diagnostics; diagnostic methods, such as liquid biopsy; next-generation sequencing (NGS), multiplex PCR, single-cell sequencing, and medical devices. In addition to drafting and prosecuting patents, Oyvind has experience with providing patentability, invalidity, and freedom-to-operate opinions, and representing patent owners on appeals and inter partes reviews before the Patent Trial and Appeal Board (PTAB). He is a member of the firm’s Chemical, Biotechnology & Pharmaceutical Practice.
Oyvind joined Foley & Lardner as an associate in 2016, and prior to that, he externed at the U.S. Patent and Trademark Office’s Office of Patent Legal Administration, where he gained experience in patent examination procedures and assessments.
Oyvind also has extensive experience as a scientist and has a Ph.D. in biochemistry. In particular, he has worked at Leidos, Inc. as a scientist, at the National Cancer Institute’s Laboratory of Protein Dynamics and Signaling as a research fellow, and at the National Cancer Institute in its Experimental Immunology Branch as a postdoctoral fellow. At the National Cancer Institute, Oyvind conducted research on the development and function of the immune system, the pathology of cancer such as multiple myeloma, stem cell function and applications, and early embryonic development.
